Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;41(9):1549-1565.
doi: 10.1007/s00296-021-04877-5. Epub 2021 May 2.

Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process

Affiliations

Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process

Rosario García-Vicuña et al. Rheumatol Int. 2021 Sep.

Abstract

To establish practical recommendations for the management of patients with psoriatic arthritis (PsA) with particular clinical situations that might lead to doubts in the pharmacological decision-making. A group of six expert rheumatologists on PsA identified particular clinical situations in PsA. Then, a systematic literature review (SLR) was performed to analyse the efficacy and safety of csDMARDs, b/tsDMARDs in PsA. In a nominal group meeting, the results of the SLR were discussed and a set of recommendations were proposed for a Delphi process. A total of 65 rheumatologists were invited to participate in the Delphi. Agreement was defined if ≥ 70% of the participants voted ≥ 7 (from 1, totally disagree to 10, totally agree). For each recommendation, the level of evidence and grade of recommendation was established based on the Oxford Evidence-Based Medicine categorisation. Particular clinical situations included monoarthritis, axial disease, or non-musculoskeletal manifestations. The SLR finally comprised 131 articles. A total of 16 recommendations were generated, all but 1 reached consensus. According to them, it is crucial to carefully analyse the impact of individual manifestations on patients (disability, quality of life, etc.), but also to recognise the impact of each drug singularities on selected clinical phenotypes to adopt the most appropriate treatment strategy. Early diagnosis and treatment to target approach, along with a close risk management, is also necessary. These recommendations are intended to complement gaps in national and international guidelines by helping health professionals address and manage particular clinical situations in PsA.

Keywords: Disease-modifying antirheumatic drugs; Manifestations; Psoriatic arthritis; Recommendations; Systematic literature review.

PubMed Disclaimer

Conflict of interest statement

All of the authors received honoraria from Pfizer for participation in this project. Francisco Rebollo and Susana Gómez work for Pfizer. Agustí Sellas has received honoraria as speaker and for consulting from Pfizer, Lilly Novartis, Janssen, Amgen. Julio Ramírez has participated at symposiums and/or advisory boards organised by Pfizer, Abbvie, MSD, UCB, Novartis, BMS, Lilly, Janssen, Amgen and Roche and his department has received research grants from Pfizer, Abbvie, Novartis and Janssen. Rubén Queiro has received honoraria as speaker, researcher and consultor from Janssen, Lilly, MSD, Abbvie, Pfizer, UCB, Celgene-Amgen, Novartis. Rosario García-Vicuña reports personal fees from Pfizer, during the conduct of the study; grants, personal fees and non-financial support from Abbvie, grants, personal fees and non-financial support from BMS, personal fees from Biogen, personal fees from Celltrion, grants, personal fees and non-financial support from Lilly, grants, personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from MSD, personal fees and non-financial support from Pfizer, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants from Janssen, outside the submitted work. Estibaliz Loza has received research grants from Janssen, Lilly, MSD, Abbvie, Pfizer, UCB, Celgene-Amgen, Roche, Abbvie, BMS, Novartis. Noemí Garrido has received personal fees from Pfizer, Abbie, Lilly, Gedeon Richter, Novartis, Sanofi y Janssen. The rest of authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Studies flow chart

Similar articles

Cited by

References

    1. Liew JW, Ramiro S, Gensler LS. Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):369–389. doi: 10.1016/j.berh.2019.01.002. - DOI - PubMed
    1. Pittam B, Gupta S, Harrison NL, Robertson S, Hughes DM, Zhao SS. Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2020;59(9):2199–2206. doi: 10.1093/rheumatology/keaa062. - DOI - PubMed
    1. Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int. 2021;41(2):275–284. doi: 10.1007/s00296-020-04775-2. - DOI - PMC - PubMed
    1. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewe RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Rodrigues Manica SA, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. doi: 10.1136/annrheumdis-2020-217159. - DOI - PMC - PubMed
    1. Kerschbaumer A, Smolen JS, Dougados M, de Wit M, Primdahl J, McInnes I, van der Heijde D, Baraliakos X, Falzon L, Gossec L. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2020;79(6):778–786. doi: 10.1136/annrheumdis-2020-217163. - DOI - PubMed

Publication types

Substances